Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646229 | 0.91 | L3MBTL1 (0.43) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL14646177 | 0.90 | CYP1A2 (0.42) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL5763556 | 0.82 | MCL1 (0.49) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL27539732 | 0.82 | IKBKB (0.45) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL9269462 | 0.82 | KDM4E (0.52) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL14560310 | 0.80 | CYP1A2 (0.42) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL9262595 | 0.78 | KDM4E (0.45) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL9272529 | 0.78 | PTPN2 (0.43) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL4180054 | 0.76 | MCL1 (0.43) | CYP1A2KDM4EALDH1A1GAAGLA | |
| SCHEMBL7826233 | 0.75 | KDM4E (0.59) | KDM4EALDH1A1GAAGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| EP-2817304-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BioChromix NewCo AB (SE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | CYP1A2 3217/4885KDM4E 4549/4885ALDH1A1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.